Results 171 to 180 of about 8,510 (199)

Lorlatinib (Lorbrena)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Lorbrena should be reimbursed by public drug plans for the treatment of adult patients with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) if certain conditions are met. Lorbrena should only be covered to treat adult patients with ALK-positive NSCLC who are diagnosed when their cancer ...
openaire   +1 more source

Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

Journal of Clinical Oncology
e20659 Background: ROS-1-positive non-small cell lung cancers (NSCLCs) are rare, accounting for approximately 1-2% of all NSCLCs. Lorlatinib is a potent, third-generation tyrosine kinase inhibitor targeting ALK and ROS1 with preclinical activity ...
S. Biter, A. Sümbül, S. Karakaya, O. Akdoğan, A. Güren, M. C. İçli, M. Büyükşimşek, E. Kut, S. Menekşe, Serhat Sekmek, Ozde Melisa Celayi̇r, Gizem Yıldırım, M. Kalender, F. Aslan, Hicran Anık, Sevgi Topçu, H. Yıldırım, Salih Tunbekici, Umut Disel, İ. Kara   +19 more
semanticscholar   +1 more source

Complete Response to Lorlatinib in Lung Adenocarcinoma With EML4-ALK Fusion Variant (E6;A18): Case Report and Literature Review.

The Journal of the National Comprehensive Cancer Network
ALK gene rearrangements represent a targetable driver in non-small cell lung cancer (NSCLC), but rare fusion variants remain poorly characterized and their sensitivity to ALK inhibitors is uncertain.
Antonio Vitale, Elisa De Paolis, Jacopo Russo, Guido Horn, A. Stefani, Alessandro Scala, Alessandra Cancellieri, Francesco D’Argento, A. Minucci, R. Trisolini, Stefano Margaritora, E. Bria, G. Tortora, E. D’Argento   +13 more
semanticscholar   +1 more source

Lorlatinib

Reactions Weekly, 2019
Wörmann, Bernhard, Griesinger, Frank, Deutsche Krebsgesellschaft. Arbeitsgemeinschaft Für Internistische Onkologie, Eberhardt, Wilfried E. E., Waller, Cornelius, Sebastian, Martin, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, Huber, Rudolf M.   +8 more
  +4 more sources

Real-world data on the efficacy and safety of iruplinalkib (WX-0593) in ALK-positive advanced lung adenocarcinoma patients previously treated with lorlatinib.

Journal of Clinical Oncology
8638 Background: Iruplinalkib (WX-0593) is a novel anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI).
Fen Wang, Zhu Li, Xiang Long, Qiushan He, Wanzhong Huang, Daying Wu, Lue Zhou   +6 more
semanticscholar   +1 more source

Evaluating activation of MAPK signaling as a potential mechanism of acquired resistance to lorlatinib in ALK-rearranged lung cancer.

Journal of Clinical Oncology
e20000 Background: The third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib has significantly advanced the clinical management of advanced ALK-rearranged non-small cell lung cancer (NSCLC).
Dongsheng Wu, Shiyou Wei
semanticscholar   +1 more source

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

JAMA Oncology
Importance ROS1 rearrangement is rare but is an attractive therapeutic target in advanced non-small cell lung cancer (NSCLC). Crizotinib, entrectinib, and repotrectinib have been approved by the US Food and Drug Administration for treatment of ROS1 ...
B. Ahn, Y. Kim, Youngjoo Lee, K. J. Suh, Se Hyun Kim, Dong-Wan Kim, Tae Min Kim, Ki Hyeong Lee, Ji-Youn Han   +8 more
semanticscholar   +1 more source

Depth of response and progression-free survival in patients with advanced ALK -positive non–small-cell lung cancer treated with lorlatinib.

Journal of Clinical Oncology
8589 Background: After 5 years of follow-up in patients with ALK -positive non-small cell lung cancer (NSCLC) treated with lorlatinib, median progression-free survival (PFS) was still not reached in the phase 3 CROWN study (NCT03052608).
R. Campelo, C. Schulz, Young Joo Min, A. Aydıner, M. Hussein, A. di Pietro, A. Polli, J-F. Martini, Hye Ryun Kim   +8 more
semanticscholar   +1 more source

Lorlatinib CROWNed

Nature Reviews Clinical Oncology, 2020
openaire   +2 more sources

Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.

Journal of Clinical Oncology
8590 Background: In an updated analysis of the CROWN study (NCT03052608), after 5 years of follow-up, lorlatinib continued to show superior efficacy over crizotinib in patients with previously untreated advanced ALK + non-small cell lung cancer
Geoffrey Liu, Ernest Nadal, S. Baijal, Alessandra Bulotta, C. Baik, H. Thurm, A. Polli, M. Nishio   +7 more
semanticscholar   +1 more source